



DT05 AUG 1 PCT/PTO 0 2 AUG 2002

Att. Docket No. REG 203B-US

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.

Bernadette B. Fahey
Bernadette B. Fahey

July 30, 2002
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of : Neil Stahl, et al.
USPN : 09/787,835
Int'l File No.: : PCT/US99/22045
Int'l File Date: : September 22, 1999
For : RECEPTOR BASED ANTAGONISTS, AND
METHODS OF MAKING AND USING
Examiner : Unknown
Group : Unknown

July 30, 2002

Commissioner for Patents
U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Transmittal of Sequence Listing

Sir:

In response to the May 30, 2002 Notification of Missing Requirements Under 35 U.S.C. 371 In The United States Designated/Elected Office (DO/EO/US) ("Notification"), Applicants enclose herewith as Exhibit 1: copy of the May 30, 2002, Notification, Exhibit 2: Sequence Listings in paper and computer-readable forms, Exhibit 3: copy of concurrently filed Amendment and Response to May 30, 2002, Notification (without exhibits) for the above-referenced patent application. A

Att. Docket No. REG 203B-US
USSN: 09 787,835
Transmittal of Sequence Listing

response to the May 30, 2002 Office Communication is due on July 30, 2002, and, therefore, this response is being timely filed.

Applicants direct the subject Sequence Listings submitted herewith be added to the specification.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R §1.821(c) and (e) respectively, are the same. I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted herewith and referred to herein in accordance with 37 C.F.R. § 1.821(g), contain no new matter.

No fee is deemed necessary for filing this paper. However, if any fees are deemed necessary, the Commissioner is hereby authorized to charge any such fees required by this paper to Deposit Account No. 18-0650.

Respectfully submitted,

Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicants
Gail M. Kempler
Reg. No. 32,143
Joseph M. Sorrentino
Reg. No. 32,598
Laura Fischer
Reg. No. 50,420
Attorneys for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Service for States having
an elected office and a designated office
Washington, DC 20590
www.uspto.gov

U.S. APPLICATION NUMBER N.	FIRST NAMED APPLICANT	ATTN. D. CHET N.
09787535	Neil Stahl	REG 213B-US

Linda O Paliadino
Regeneron Pharmaceuticals Inc
777 Old Saw Mill River Road
Tarrytown, NY 10591

INTERNATIONAL APPLICATION NO.	
PCT US99 22045	
1A FILING DATE	PRIORITY DATE
09 22 1998	09 25 1998

CONFIRMATION NO. 8053
371 FORMALITIES LETTER



OC0000000982C2816

Date Mailed: 05/30/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.135(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reasons:

- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy, or compact disc, as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing"
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
- For Rules Interpretation, call (703) 306-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
- This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

SHAKEEL AHMED

Telephone: (703) 305-3659

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO	INTERNATIONAL APPLICATION NO	ATTY DOCKET NO
09/787,835	PCT/US99/22045	REG 203B-US